Association Between Myocardial Scar Burden and Left Ventricular Ejection Fraction in Ischemic Cardiomyopathy

Fatma Aboul Enein 1, 2, Sarah Aliaaboun 3, Samih Khayyat 3, Mariam Andijani 3, Mazen M. Alkhuzai 3, Aseel A. Aljunied 3, Magdi Al Adhreai Sr. 2

1. Cardiology, Alexandria University Faculty of Medicine, Alexandria, EGY 2. Cardiology, King Abdullah Medical City, Mecca, SAU 3. Cardiology, Faculty of Medicine, Umm Al-Qura University, Mecca, SAU

Corresponding author: Fatma Aboul Enein, aboulenein99@yahoo.com

Abstract

Background
This study was conducted to assess the relationship between scar burden (extent and severity) and the follow-up left ventricular ejection fraction (LVEF).

Methods
Patients were referred for viability assessment with late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging. To measure the transmural extent of LGE in each segment (scar score), we used a five-point scale system. Baseline ejection fraction (EF) and at follow-up were recorded. LVEF classified as non-severe and severely depressed.

Results
The study included 178 patients (males: 88.8%; mean age: 57.1±10.02 years; mean baseline LVEF: 28.61±10.39). In patients with severe baseline LVEF, the mean scar percentage was higher than that in patients who had non-severe LVEF (38.8±19.41 vs. 24.61±21.21; p<0.001). On linear regression analysis, aldosterone antagonist and total scar score significantly predicted follow-up ejection fraction (EF) (B=-7.083, p<0.001 and B=-3.038, p=0.038, respectively). Left anterior descending artery (LAD) territory viability and baseline EF significantly predicted change in EF in patients with LVEF ≤ 35% (B=5.389, p=0.009 and B=-0.581, p<0.001, respectively). On binary regression analysis for the prediction of at least 5% improvement in EF in patients with baseline EF ≤ 35%, baseline EF and LAD viability were significant (B=-0.15, p=0.014 and B=1.042 and p=0.054, respectively).

Conclusions
The extent of myocardial scar and viability of LAD territory are identified as the important and independent parameters for the predictions of improvement in EF even after adjustment for demographics and baseline EF and following the standards of care medication.

Keywords: ischemic cardiomyopathy, viability, cad, prognosis, mri cardiac, heart failure with reduced ejection fraction

Introduction
Magnitude of the problem
Currently, more than five million patients have been diagnosed with heart failure (HF), with the figures still rising and over 650,000 new cases diagnosed annually [1]. Although the survival of HF patients have improved, the absolute mortality rates of HF patients remains 50% if diagnosed within five years of its occurrence [2]. Coronary artery disease (CAD) with a history of myocardial infarction (MI) is a major cause of HF with reduced ejection fraction (EF) and ischemic cardiomyopathy (ICM). [3] It is estimated that CAD may cause more than 11 million deaths globally [4] in the next 20 years [5]. Mortality rates in ICM patients with severely depressed EF are significantly higher than the general patient [6]. Despite significant advancements in medical and device therapies, outcomes in severe HF are non-satisfactory.

Cardiac magnetic resonance imaging (CMR)
For the evaluation of viability and subsequent effects of clinical management plan, cardiac magnetic resonance imaging (CMR) is the gold standard, and using a paramagnetic contrast agent (gadolinium), scar can be identified using as late gadolinium enhancement (LGE). With increase in extracellular space due to
fibrosis, the gadolinium-based contrasts wash out slowly from the myocardium, which enhances areas of scarring. Scarring may be observed in both ischemic and non-ischemic cardiomyopathy; the former extends from the subendocardium to the epicardium and is matched to the area of infarction related artery [7]. Myocardial infarction (MI) causes scar in the myocardium, which affects the left ventricle (LV) contractile function and results in the reduction of systolic function.

CMR is useful in exploring the correlation between size of myocardial scar, localization, and transmurality of long-term LV remodeling of healed MI patients [8]. The quantity and transmural extent of myocardial scar tissues on LGE are predictors of mortality in patients with CAD that were independent from reduced LVEF [9].

The aim of this study is twofold: firstly, to investigate the relation between scar burden (extent and severity) and follow-up EF in ICM, and, secondly, to identify predictors of EF improvement.

Materials And Methods

After local Institutional Review Board approval, we identified 500 consecutive patients who had undergone CMR for viability assessment from 2012 to 2018. Patients with non-CAD cardiomyopathies were not included in this study. Data were collected from the electronic medical files. Data recorded included demographics, medication, echocardiography, coronary angiogram, and CMR results. Medications included β-blockers, angiotensin-converting enzyme inhibitors (ACE-I), spironolactone, and statins. Post-CMR study coronary revascularization (either percutaneous or surgical) was also recorded.

Echocardiography protocol

The American Society of Echocardiography guidelines were followed to review echocardiogram reports. LVEF was classified as follows: non-severe LVEF was defined as LVEF > 35%, and severely abnormal was defined as LVEF ≤ 35%. In patients with follow-up echocardiography, LVEF was calculated using the Simpson biplane method by an echocardiographer (F. A.) blinded from clinical analysis. An improvement in LVEF ≥ 5% was used to define global functional recovery from responders [10].

CMR protocol and analysis

CMR study was conducted using a MAGNETOM Espree 1.5-Tesla MRI (Siemens, Malvern, PA, USA). CMR images were evaluated by an experienced cardiologist with level II certified training (F. A.) blinded from clinical analysis. Semiquantitative analysis was performed using a 17-segment model [11]. To define the transmural extent of LGE in each segment, a five-point scale was followed, where the scar score was given as follows: 0 = no LGE; 1 = 1%-25% LGE; 2 = 26%-50% LGE; 3 = 51%-75% LGE; and 4 = 76%-100% LGE. Transmural extent of a segment with LGE 1-50% was considered as "viable" and with LGE 51-100% as "scar" [12]. Based on scar transmurality, each segment was scored. LV scar score (LVSS) was calculated as a sum of the scores of all the segments dividing by 17. LVSS of 0 represents no scar. To know the extent of scar tissues, quantitative analysis was performed on the basis of following parameters: viable segments with a scar score of 0, 1, or 2, and nonviable segments with a scar score of 3 or 4.

Statistical analysis

SPSS Version 21 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis of data. Continuous data were expressed as mean ± SD and compared using Student’s t-test. Categorical data were expressed as percentages and compared using a chi-square test. Regression models were used, and variables with a p-value of <0.05 as tested on univariate analysis were incorporated into the multivariate models as continuous or dichotomous variables. A p-value of <0.05 was considered statistically significant.

Results

Table 1 summarizes the baseline characteristics, coronary angiographic results, CMR results, and medication. A total of 178 consecutive patients were referred for CMR viability, with an average age of 57.1±10.0 years and with a mean baseline LVEF% of 28.6±10.4. Of the patients, 88.8% were males; 67.5% had multivessel disease, and in 64.6% the left anterior descending artery (LAD) territory was non-viable. Patients were categorized into group based on their baseline LVEF: group I (LVEF < 35%) and group II (LVEF > 35%). Most of patients in group I had multivessel disease (65.1%) as compared to group II (44.1%) (p=0.02).

Regarding change in EF (follow-up EF and baseline EF) there was no significant difference between the two groups. A total of 42 patients underwent revascularization, of those 38% demonstrated improvement in LVEF.
|                          | Whole Cohort (n=178) | Group I: EF ≤ 35% (n=144) | Group II: EF > 35% (n=34) | p-Value |
|--------------------------|----------------------|---------------------------|---------------------------|---------|
| **Clinical data**        |                      |                           |                           |         |
| Male, n (%)              | 158 (88.8)           | 132 (91.7)                | 26 (76.4)                 | 0.012   |
| Age, years, mean±SD      | 57.1±10.02           | 57.0±9.95                 | 57.4±10.5                 | 0.83    |
| BMI, mean±SD             | 28±5.2               | 27.8±5.2                  | 28.9±4.9                  | 0.225   |
| HTN, n (%)               | 118 (66.3)           | 99 (68.8)                 | 19 (55.8)                 | 0.153   |
| DM, n (%)                | 123 (69.1)           | 104 (72.2)                | 19 (55.8)                 | 0.064   |
| Smoking, n (%)           | 35 (19.7)            | 23 (15.9)                 | 12 (35.2)                 | 0.012   |
| Baseline EF (%)          | 28.6±10.4            |                           |                           |         |
| **Number of significantly diseased coronaries** | | | | |
| Single-vessel disease, n (%) | 27 (17.2)           | 17 (11.8)                 | 10 (29.4)                 |         |
| Two-vessel disease, n (%) | 19 (12.1)            | 17 (11.8)                 | 2 (5.8)                   | 0.02    |
| Three-vessel disease, n (%) | 106 (67.5)          | 91 (63.1)                 | 15 (44.1)                 |         |
| **Medications and revascularization** | | | | |
| Aspirin, n (%)           | 174 (97.8)           | 140 (97.2)                | 34 (100)                  | 0.326   |
| Statin, n (%)            | 162 (91)             | 131 (90.9)                | 31 (91.1)                 | 0.97    |
| β-blocker, n (%)         | 176 (98.9)           | 143 (99.3)                | 33 (97)                   | 0.264   |
| ACE-I, n (%)             | 136 (76.4)           | 115 (79.8)                | 21 (61.7)                 | 0.025   |
| Aldosterone antagonist, n (%) | 102 (57.3)         | 94 (65.2)                 | 8 (23.5)                  | <0.001  |
| Revascularization, n (%) | 42 (23.6%)           | 35 (24.3%)                | 7 (20.5%)                 | 0.646   |
| **Imaging results**      |                      |                           |                           |         |
| Baseline EF (%)          | 28.6±10.4            |                           |                           |         |
| Number of non-viable segment, mean±SD | 3.76±3.2 | 4.09±3.18 | 2.35±3.01 | 0.004 |
| Segment %, mean±SD       | 36.1±20.5            | 38.8±19.41                | 24.6±21.21                | <0.001  |
| **LAD territory**        |                      |                           |                           |         |
| Viable, n (%)            | 63 (35.4)            | 41 (28.4)                 | 22 (64.1)                 | <0.001  |
| Non-viable, n (%)        | 115 (64.6)           | 103 (71.5)                | 12 (35.2)                 |         |
| **Follow-up echocardiography** | | | | |
| Change in EF%            | 4.9±9.4             | 5.5±9.7                   | 2.35±6.7                  | 0.207   |
| LVEF improvement of ≥5%, n (%) | 58 (32.6)         | 49 (34)                   | 9 (26.4)                  | 0.39    |
| LVEF improvement of >5% in revascularization subgroup | 16 of 42 (38%) | 15 of 35 (42%) | 1 of 7 (14%) | 0.155 |

**TABLE 1: Baseline characteristics based on severity of EF**

EF, ejection fraction; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; ACE-I, angiotensin-converting enzyme inhibitors; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction

Table 2 summarizes predictors of changes in EF in all patients using linear regression analysis. Significant predictors identified in univariable analysis were hypertension, diabetes mellitus (DM), aldosterone antagonist, total scar score, and LAD territory. However, in multivariable analysis, only aldosterone antagonist and the LVSS were found to be significant after adjusting for LAD territory viability. An
interaction was observed between the LAD viability and total scar score.

### TABLE 2: Linear regression analysis for the predictors of change in EF in whole cohort

| Factor                | Univariable Analysis | Multivariable Analysis |
|-----------------------|----------------------|------------------------|
|                       | Odd’s ratio  | p-Value  | 95% CI          | Odd’s ratio | p-Value | 95% CI          |
| Age                   | -0.003     | 0.976    | -0.23 to 0.23  |             |         |               |
| HTN                   | -5.654     | 0.014    | -10.16 to -1.15| -3.911      | 0.144   | -9.18 to 1.36  |
| DM                    | -4.944     | 0.038    | -9.68 to -0.29 | -1.047      | 0.704   | -6.49 to 4.40  |
| Smoking               | -3.133     | 0.184    | -7.83 to 1.56  |             |         |               |
| Statin                | 0.150      | 0.968    | -6.32 to 7.62  |             |         |               |
| ACE-I                 | -2.980     | 0.277    | -8.38 to 2.43  |             |         |               |
| Aspirin               | 4.147      | 0.512    | -8.37 to 16.66 |             |         |               |
| Aldosterone antagonist| -8.088     | 0.000    | -12.13 to -4.04| -7.083      | 0.000   | -10.95 to -3.22|
| Revascularization     | 2.59       | 0.28     | -2.12 to 7.81  |             |         |               |
| Number of vessels     | -2.24      | 0.07     | -4.63 to 0.16  |             |         |               |
| LVSS                  | -4.15      | 0.003    | -6.85 to -1.46 | -3.038      | 0.038   | -5.9 to -0.2   |
| Scar percentage       | -0.17      | 0.003    | -0.27 to -0.09 |             |         |               |
| Transmurality         | -0.85      | 0.011    | -1.50 to -0.200|             |         |               |
| LAD territory viability| 6.39       | 0.003    | 2.19 to 10.61  | 3.488       | 0.126   | -1.0 to 7.98   |
| Number of viable segments | 0.852 | 0.011 | 0.200 to 1.503 |             |         |               |

HTN, hypertension; DM, diabetes mellitus; ACE-I, angiotensin-converting enzyme inhibitors; LVSS, left ventricular scar score; LAD, left anterior descending artery; EF, ejection fraction.

Table 2 shows linear regression analysis for the predictors of change in EF in whole cohort. Only baseline EF and presence of LAD viability were independent predictors for change in EF on follow-up.

### TABLE 3: Linear regression analysis for the predictors of change in EF in group I (baseline EF ≤ 35%)

| Factor                | B  | p-Value  | 95% CI          |
|-----------------------|----|----------|-----------------|
| Age                   | 0.049 | 0.648    | -0.163 to 0.260 |
| DM                    | -3.340 | 0.150    | -7.915 to 1.235 |
| ACE-I                 | -0.300 | 0.911    | -5.651 to 5.050 |
| Aldosterone antagonist| -2.200 | 0.326    | -6.360 to 2.231 |
| LAD territory viability| 5.389 | 0.009    | 1.407 to 9.371  |
| Baseline EF           | -0.581 | 0.000    | -0.861 to -0.302|

DM, diabetes mellitus; ACE-I, angiotensin-converting enzyme inhibitors; LAD, left anterior descending artery; EF, ejection fraction.

Table 3 shows linear regression analysis for the predictors of change in EF in group I (baseline EF ≤ 35%). Only baseline EF and presence of LAD viability were independent predictors for change in EF on follow-up.
**TABLE 4: Multivariable binary regression analysis for the prediction of at least 5% improvement in EF in patients with baseline EF ≤ 35% (group I)**

| Factor                  | B       | p-Value | 95% CI       |
|-------------------------|---------|---------|--------------|
| Age                     | 0.023   | 0.402   | 0.970 - 1.078|
| DM                      | -1.121  | 0.072   | 0.096 - 1.106|
| Aldosterone antagonist  | -0.980  | 0.108   | 0.113 - 1.241|
| LAD territory viability | 1.042   | 0.054   | 0.981 - 0.190|
| Baseline EF             | -0.150  | 0.014   | 0.828 - 0.979|

DM, diabetes mellitus; LAD, left anterior descending artery; EF, ejection fraction

**Discussion**

The objective of this study was to identify the prognostic role of scar burden in ICM. Our results revealed that the follow-up LVEF is influenced by scar burden, as evident by total scar scores. Furthermore, we observed that LAD viability is an independent predictor of follow-up LVEF, and conversely revascularization did not affect follow-up LVEF.

**Pathophysiology of myocardial infarction and hibernation**

Myocardium may exist in different physiological states, namely normal, hibernating, and nonviable. First observed changes (10-15 minutes after the onset of ischemia) are loss of cellular glycogen, myofibrils relaxation, and disruption in sarcolemma. Using electron microscopy, mitochondrial abnormalities were noted after 10 minutes of coronary occlusion and they were progressive [13]. Progression in necrosis from the subendocardium to subepicardium occurs over several hours. Collateral flow, myocardial oxygen consumption, and intermittent occlusion/reperfusion are the important factors affecting precondition of the heart [14].

**Histopathological changes of scar by CMR**

Hibernating myocardium is dysfunctional, viable, and capable of recovering the function after reperfusion [15]. Gunning et al. in a study on CMR and myocardial biopsy showed that the hibernating myocardium contain myocyte content that is similar to normally perfused myocardium but it was significantly higher than the scar areas [16]. Ventricular biopsies taken at coronary artery bypass grafting (CABG) reported morphological changes characterized by myocyte de-differentiation and loss of sarcomeres, sarcoplasmic reticulum, and T-tubules (contractile apparatus) [17].

Despite the preserved numbers, histopathological variations were associated with abundance in glycogen deposition, rough endoplasmic reticulum strands, and reduced consumption of mitochondrial oxygen. These changes were perfusion dependent, more in endocardium, and directly correlate with the severe condition of stenosis in subtending coronary artery [17]. Research studies support the model of hibernation as the chronic adaptive response, which can eventually become irreversible [18]. Regression in glycogen accumulation and restoration of myofibril content could be possible; however, the myocardial fibrosis is not reversible [16].

**Hibernating myocardium and contractile improvement**

In a study of the timeline of contractile function improvement in hibernating myocardium, 31% of the hibernating segments improved at third month and 61% showed additional recovery at 14 months [19]. This is in agreement with our findings, where 58 patients (32.5%) showed a >5% improvement in LVEF; however, only 42 (23.6%) had revascularization (percutaneous coronary intervention [PCI] or CABG). The lower frequency of revascularization may be in part attributed to patient or surgeon decision. The result could be explained in part by the ORBITA trial, where patients on optimal medical treatment had similar outcomes as those on PCI [20].

**CMR scar extent and functional improvement**

Myocardial viability is pivotal to the clinical decision plan in managing ICM. Assessment of scar extent and/or fibrosis and its size using LGE-CMR is accurate and reproducible. Several studies have been conducted to estimate the extent, and LGE amount as an important parameter for an independent prediction of functional recovery and outcome. With LGE, one can predict the major adverse cardiac events and the
mortality rate beyond the coronary anatomy or clinical factors, which is independent of EF [21]. The transmurality of scar is inversely related to functional recovery. Segments with >50% scar (non-viable) have a low probability of functional recovery [22]. The presence of >10 segments with viability predicts a global functional recovery [23]. The presence of 44 scar segments (25% of LV) is a close-off limit to predict LVEF improvement [24]. This is in agreement with the findings of our study where the total scar score was observed as an independent predictor of LVEF improvement after an adjustment for DM and other medications. Remodeling of LV with large ended systolic volume can prevent the global recovery, even in the patients with substantial viability. Improvement of LVEF may be observed within one year of post-revascularization [19].

Ischemic cardiomyopathy: optimal medical treatment and prognosis

Medical treatment of the patients with HF has improved substantially with the introduction of ACE-I, angiotensin II receptor blockers, spironolactone, and β-blockers. However, in patients with severe HF, the mortality rate remains high. Survival rate estimates were 50% and 10% at 5 and 10 years, respectively [25]. After CABG, contractile function improves in one-third segments and LVEF improves in only 40% patients [26]. In clinical practices, LVEF is important for patient prognostics. Hence, improved LVEF may affect prognosis, at least in parts. Identification of patients with potential to improve LVEF is important for survival, risk stratification, and clinical management plan. A recent meta-analysis of 5,286 patients concluded that the optimal medical strategy is comparable to revascularization strategy regarding prognosis, death, MI, repeat revascularization, or angina [27]. This was the management strategy taken by the majority of patients observed during our study, and only one-third underwent revascularization.

Impact of scar and disease progression

LVEF is considered a strong predictor of sudden cardiac death among the clinical observations, but delay in hyperenhancement MRI may recognize myocardial scar, which is a substrate of developing a probably fatal ventricular arrhythmia. Klem et al. [28] also observed a strong prognostic ability of myocardial scar burden for the prediction of adverse outcomes, which suggests that quantification of scar was superior to LVEF < 30% to recognize high-risk patients. They studied 157 patients, out of which 53% were with ICM and 25/65 patients with LVEF < 30% died or had an appropriate implantable cardioverter-defibrillator (ICD) discharge at the time of follow-up. Patients with scar < 5% were having event rate below or similar to entire group with LVEF > 30% and were at a low risk. Furthermore, Gao et al. [29] reported that the scar observed through the CMR provides a prediction on arrhythmic events in patients assessed for ICD implantation. However, it is important to note that both the studies considered non-ICM as well as ICM patients.

Role of revascularization

In this study, 42 (23.6%) patients had undergone revascularization by either PCI or CABG after CMR. A non-significant difference was noted in the rate of LVEF improvement and the scar score. The role of revascularization in ICM is still not determined. Gerber et al. have reported that the survival rate was significantly worse when there was no revascularization of dysfunctional viable myocardium [30]. A multicenter study called the HF Revascularization Trial (HEART) was performed on 800 ICM patients and explained that the conservative management strategy may not be inferior to revascularization [18].

Clinical relevance

LVEF is well accepted as one of the strong predictors of sudden cardiac death; CMR is the gold standard for identifying myocardial scar and viability. An important aspect of our study is quantifying scar burden as determined by the magnitude of LGE, hence giving a global view of the heart rather than focusing on viability in a binary fashion. Our data reveal that the quantification of scar burden could offer more risk stratification in ICM patients and may identify the cases with more disease progression even after optimal medical treatment and those who may be candidates for device implantation.

Conclusions

In ICM, myocardial scar burden and viability of LAD territory are independent prognostic predictors even after adjustment for demographics, baseline EF, and medications.

Additional Information

Disclosures

**Human subjects:** Consent was obtained by all participants in this study. King Abdullah Medical City IRB (18-429). **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICME uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the


References

1. Go AS, Mozaffarian D, Roger VL, et al.: Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013, 127:145-152. 10.1161/CIR.0b013e318229abef

2. Levy D, Kneschue S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002, 347:1597-1602. 10.1056/NEJMoa022065

3. Yancy CW, Jessup M, Bozkurt B, et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 128:240-327. 10.1161/CIR.0b013e3182e775

4. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLOS Med. 2006, 3:442. 10.1371/journal.pmed.0030442

5. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol. 2007, 50:2173-2195. 10.1016/j.jacc.2007.09.011

6. Eekowszisz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA: Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009, 53:15-20. 10.1016/j.jacc.2008.08.067

7. Kim RJ, Albert TS, Wilhe JL, et al.: Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008, 117:629-637. 10.1161/CIRCULATIONAHA.107.723262

8. Orr S, Manhenke C, Anand IS, Squire I, Nagel E, Edvardsen T, Dickstein K: Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol. 2007, 99:1109-1114. 10.1016/j.amjcard.2006.11.059

9. Wu E, Ortiz JT, Tejedor P, et al.: Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008, 94:730-736. 10.1136/hrt.2007.122622

10. Lang RM, Bierig M, Devereux RB, et al.: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18:1440-1465. 10.1016/j.echo.2005.10.005

11. Cerqueira MD, Weissman NJ, Dilsizian V, et al.: American Heart Association Writing Group on Myocardial S, Registration for Cardiac I: standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002, 105:539-542. 10.1161/hc0402.102975

12. Kelle S, Roes SD, Klein C, et al.: Prognostic value of myocardial infarct size and contracture reserve using magnetic resonance imaging. J Am Coll Cardiol. 2009, 54:1770-1777. 10.1016/j.jacc.2009.07.027

13. Virmani R, Forman M, Kolodgie F: Myocardial reperfusion injury. Histopathological effects of perfluorochemical. Circulation. 1990, 81:57-68.

14. Reimer KA, Jennings RB, Tatum AH: Pathobiology of acute myocardial ischemia: metabolic, functional, and ultrastructural studies. Am J Cardiol. 1985, 52:72-81. 10.1016/0002-9149(85)90180-7

15. Raj V, Agrawal SK: Ultrastructural studies. Pathobiology of acute myocardial ischemia. Postgrad Med. 2010, 86:532-540. 10.1136/pgmj.2009.095856

16. Gunning MG, Kaprielian RR, Pepper J, et al.: The histology of viable and hibernating myocardium in relation to imaging characteristics. J Am Coll Cardiol. 2002, 39:428-435. 10.1016/S0735-1097(02)01766-1

17. Borgers M, Thoné F, Wouters L, Ausma J, Shivalkar B, Flameng W: Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis: chronic hibernation?. Circ Cardiovasc Pathol. 1993, 2:237-245. 10.1016/1054-8807(93)90030-6

18. Cleland JGF, Calvert M, Freemantle N, et al.: The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011, 13:227-235. 10.1093/eurjhf/hft250

19. Bax JJ, Visser FG, Poldermans D, et al.: Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation. 2001, 104:514-518.

20. Al-Lamee R, Thompson D, Debihi HM, et al.: Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018, 391:51-60. 10.1016/S0140-6736(17)32714-9

21. Gerber BL, Garot J, Blumenke DA, Wu KC, Lima JAC: Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation. 2002, 106:1085-1089. 10.1161/01.CIR.0000057818.15792.1E

22. Choi RM, Kim RJ, Gubernikoff G, Vargas ID, Parker M, Jadd RM: Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001, 104:1101-1107. 10.1161/01.CIR.0000035105.096798

23. Cheong BYC, Muthupillai R, Wilson JM, et al.: Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009, 120:2069-2076. 10.1161/CIRCULATIONAHA.109.852517

24. Egg TJ, Selvanayagam JB, Jennifer J, et al.: Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010, 12:56-56. 10.1186/1532-429X-12-56

25. Roger VL: Epidemiology of heart failure. Circ Res. 2013, 113:646-659. 10.1161/CIRCRESAHA.113.300268

26. Bax JJ, van der Wall EE, Harbinson M: Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart. 2004, 90:26-33. 10.1136/hrt.2002.007575
27. Stergiopoulos K, Boden WE, Hartigan P, et al.: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014, 174:232-240.
10.1001/jamainternmed.2013.12855
28. Klem I, Weinsaft JW, Bahnson TD, et al.: Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012, 60:408-420.
10.1016/j.jacc.2012.02.070
29. Gao P, Yee R, Gula L, et al.: Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circulation. 2012, 5:448-456.
10.1161/CIRCIMAGING.111.971549
30. Gerber BL, Rousseau MF, Ahn SA, et al.: Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol. 2012, 59:825-835. 10.1016/j.jacc.2011.09.073